MRI, Efficacy, and Safety of Tolebrutinib in Patients with Highly Active Disease (HAD): 2- Year Data from the Phase 2b Long-term Safety (LTS) Study

Authors
Category Primary study
JournalNeurology
Year 2023
This article has no abstract
Epistemonikos ID: 0d4223fcbeabc0e7ad3110c40f2f09ee5b28a7c2
First added on: Feb 16, 2025